Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis
Does human homology reduce the potential immunogenicity of non-antibody scaffolds?

Immunogenicity risk assessment of synthetic peptide drugs and their impurities
Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect